Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Short Interest Down 70.0% in June

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) saw a significant decline in short interest in June. As of June 30th, there was short interest totaling 101,413 shares, a decline of 70.0% from the June 15th total of 337,919 shares. Approximately 8.3% of the shares of the stock are short sold. Based on an average trading volume of 158,411 shares, the short-interest ratio is currently 0.6 days.

Aspire Biopharma Stock Down 0.7%

Shares of NASDAQ ASBP opened at $5.97 on Tuesday. The firm’s fifty day moving average is $5.72 and its 200 day moving average is $35.54. Aspire Biopharma has a 52 week low of $3.31 and a 52 week high of $1,050.36. The company has a market cap of $7.76 million, a price-to-earnings ratio of -0.05 and a beta of 0.15.

Aspire Biopharma (NASDAQ:ASBP) last issued its quarterly earnings data on Friday, May 15th. The company reported ($20.57) earnings per share for the quarter. The firm had revenue of $0.03 million during the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aspire Biopharma in a research note on Monday, April 20th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Hedge Funds Weigh In On Aspire Biopharma

Several large investors have recently made changes to their positions in the business. CIBC Bancorp USA Inc. purchased a new stake in shares of Aspire Biopharma in the 3rd quarter worth approximately $28,000. Jane Street Group LLC raised its stake in Aspire Biopharma by 625.8% during the second quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock valued at $41,000 after buying an additional 131,533 shares during the last quarter. Finally, XTX Topco Ltd boosted its holdings in Aspire Biopharma by 853.2% in the fourth quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock worth $35,000 after acquiring an additional 237,620 shares in the last quarter. 19.17% of the stock is currently owned by hedge funds and other institutional investors.

Aspire Biopharma Company Profile

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.